Schedule III Tax Relief for Cannabis: What Rescheduling Means for Operators

Executive Summary

The rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act represents the most significant federal tax reform opportunity for the U.S. cannabis industry since state-level legalization began in 2012. Multi-state operators including Trulieve Cannabis Corp., Curaleaf Holdings, and Green Thumb Industries stand to gain hundreds of millions of dollars in annual tax relief through the elimination of Internal Revenue Code Section 280E restrictions, which currently prohibit cannabis businesses from deducting ordinary business expenses. The Drug Enforcement Administration initiated formal rulemaking proceedings in May 2024 following a recommendation from the Department of Health and Human Services, with the administrative process expected to conclude in late 2024 or early 2025. Industry analysts project that Schedule III reclassification could improve operating margins for publicly traded cannabis companies by 15 to 40 percentage points, fundamentally altering capital allocation strategies, acquisition activity, and competitive dynamics across the $30 billion U.S. cannabis market. The tax relief extends beyond cultivation and retail to ancillary businesses, creating ripple effects throughout supply chains in states with established medical and adult-use programs.

Why Schedule III Tax Relief Matters

The financial impact of Schedule III reclassification will exceed $2 billion annually in aggregate tax savings for U.S. cannabis operators, according to investment research published by Cantor Fitzgerald in June 2024. This represents the single largest regulatory catalyst for cannabis equity valuations since the 2018 Farm Bill removed hemp from controlled substance scheduling. The current tax burden under Section 280E forces cannabis companies to pay effective federal tax rates between 70% and 90% of gross profit, compared to the standard 21% corporate rate applied to other industries. Trulieve, which operates 193 dispensaries across 11 states, reported $2.1 billion in revenue for fiscal year 2023 but paid approximately $320 million in federal taxes that would have been substantially lower under normal deduction rules. For patients, Schedule III status indirectly affects access and pricing. Lower tax burdens allow operators to reduce retail prices, invest in product development, and expand into underserved markets. Medical cannabis patients in states like Pennsylvania and Ohio, where program costs remain prohibitively high for many households, could see 10% to 20% price reductions as operators pass savings downstream. The rescheduling also legitimizes cannabis in the eyes of institutional capital. Banks, insurance providers, and pension funds that currently avoid the sector due to Schedule I classification have indicated willingness to enter the market once Schedule III status takes effect, according to statements from the American Bankers Association in testimony before the Senate Banking Committee in March 2024.

Background and History: From Prohibition to Rescheduling

Cannabis has been classified as a Schedule I controlled substance under the Controlled Substances Act since the statute's enactment in 1970, placing it in the most restrictive category alongside heroin and LSD.

The Controlled Substances Act of 1970

Congress passed the Controlled Substances Act as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, codified at 21 U.S.C. § 801 et seq. The statute established five schedules of controlled substances based on medical use, abuse potential, and safety. Schedule I substances are defined as having no currently accepted medical use, high potential for abuse, and lack of accepted safety for use under medical supervision. Cannabis was placed in Schedule I despite objections from the American Medical Association, which argued that the classification was premature given ongoing medical research.

Section 280E: The 1982 Tax Code Amendment

Internal Revenue Code Section 280E, enacted in 1982, prohibits businesses trafficking in Schedule I or Schedule II controlled substances from deducting ordinary and necessary business expenses. Congress added Section 280E in response to a Tax Court case, Edmondson v. Commissioner, in which a cocaine dealer successfully claimed business expense deductions. The provision states: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted." Cannabis businesses can deduct cost of goods sold under Section 471, but cannot deduct rent, salaries, marketing, utilities, or other operating expenses. This creates effective tax rates of 70% to 90% on gross profit.

State-Level Legalization: 1996 to Present

California became the first state to legalize medical cannabis with the passage of Proposition 215 in 1996. Colorado and Washington legalized adult-use cannabis in 2012, with sales commencing in 2014. As of August 2024, 38 states have legalized medical cannabis, and 24 states plus the District of Columbia have legalized adult-use cannabis. Despite state-level legalization, cannabis remains federally illegal, creating the legal paradox that subjects state-licensed operators to Section 280E.

The Cole Memorandum and Obama-Era Enforcement Policy

In August 2013, Deputy Attorney General James Cole issued a memorandum directing federal prosecutors to deprioritize enforcement against state-compliant cannabis businesses. The Cole Memorandum established eight federal enforcement priorities, including preventing distribution to minors and preventing diversion to states where cannabis remained illegal. This policy created a de facto safe harbor for state-licensed operators, though it did not resolve the Section 280E tax burden. Attorney General Jeff Sessions rescinded the Cole Memorandum in January 2018, creating renewed uncertainty, though actual enforcement patterns did not significantly change.

The 2018 Farm Bill and Hemp Descheduling

The Agriculture Improvement Act of 2018, commonly known as the Farm Bill, removed hemp—defined as cannabis containing less than 0.3% delta-9 THC—from the Controlled Substances Act. This created a legal market for CBD derived from hemp, though it did not affect the scheduling status of cannabis containing higher THC concentrations. The Farm Bill demonstrated that Congress could modify controlled substance scheduling through legislation, though comprehensive cannabis reform remained politically elusive.

The Biden Administration's Rescheduling Initiative

On October 6, 2022, President Joe Biden directed Secretary of Health and Human Services Xavier Becerra and Attorney General Merrick Garland to review the federal scheduling of cannabis. Biden issued a statement saying, "I am announcing three steps that I am taking to end this failed approach. First, I am pardoning all prior federal offenses of simple marijuana possession... Second, I am urging governors to pardon state offenses of simple marijuana possession... Third, I am asking the Secretary of Health and Human Services and the Attorney General to expeditiously review how marijuana is scheduled under federal law." The Department of Health and Human Services conducted a scientific and medical evaluation through the Food and Drug Administration. On August 29, 2023, HHS delivered its scheduling recommendation to the DEA, though the contents remained confidential under administrative procedure rules. Bloomberg News reported in August 2023 that HHS had recommended moving cannabis to Schedule III.

DEA Notice of Proposed Rulemaking

On May 16, 2024, the Drug Enforcement Administration published a Notice of Proposed Rulemaking in the Federal Register proposing to reschedule cannabis from Schedule I to Schedule III. The NPRM, titled "Schedules of Controlled Substances: Rescheduling of Marijuana," cited the HHS recommendation and opened a 60-day public comment period. The DEA received over 43,000 comments, representing the highest volume of public input on any controlled substance scheduling action in agency history. The NPRM stated that cannabis has currently accepted medical use in treatment in the United States, moderate to low potential for abuse relative to Schedule II substances, and moderate or low potential for physical or psychological dependence. These findings directly contradicted the criteria that had kept cannabis in Schedule I for 54 years.

Administrative Law Judge Hearing

Following the comment period, the DEA announced in July 2024 that it would convene an administrative law judge hearing to take additional testimony from stakeholders. The ALJ hearing, scheduled for November 2024, will allow opponents of rescheduling—including Smart Approaches to Marijuana and certain law enforcement organizations—to present evidence. The ALJ will issue a recommended decision to the DEA Administrator, who retains final authority to promulgate the rule.

Key Players in the Rescheduling Process

Drug Enforcement Administration

The DEA holds exclusive authority to schedule and reschedule controlled substances under 21 U.S.C. § 811. DEA Administrator Anne Milgram oversees the rescheduling process. The agency has historically opposed cannabis liberalization, making the May 2024 NPRM a significant policy shift. The DEA must consider eight factors in scheduling determinations: actual or relative potential for abuse; scientific evidence of pharmacological effect; current scientific knowledge; history and current pattern of abuse; scope, duration, and significance of abuse; risk to public health; psychic or physiological dependence liability; and whether the substance is an immediate precursor of a controlled substance.

Department of Health and Human Services

The HHS, through the FDA, conducts the scientific and medical evaluation that informs DEA scheduling decisions. HHS Secretary Xavier Becerra oversaw the evaluation that produced the August 2023 recommendation. The FDA's analysis included review of over 30,000 pages of scientific literature, consultation with the National Institute on Drug Abuse, and assessment of state medical cannabis programs.

Multi-State Operators

Trulieve Cannabis Corp., headquartered in Quincy, Florida, operates the largest retail footprint in the U.S. cannabis industry with 193 dispensaries. The company reported $1.4 billion in revenue for the first nine months of 2023 and paid approximately $240 million in federal taxes. Chief Executive Officer Kim Rivers stated in an August 2024 earnings call that Schedule III tax relief would improve operating margins by approximately 30 percentage points. Curaleaf Holdings, based in Wakefield, Massachusetts, operates 151 dispensaries across 17 states. The company reported $1.3 billion in revenue for fiscal year 2023 and estimated that Section 280E added $180 million to its federal tax liability. Green Thumb Industries, headquartered in Chicago, operates 93 retail locations across 15 states. The company reported $1.0 billion in revenue for fiscal year 2023 and projected that Schedule III status would generate $120 million in annual tax savings.

Cannabis Trade Associations

The National Cannabis Industry Association, representing over 1,500 member companies, submitted comments to the DEA supporting rescheduling and urging expedited implementation. NCIA Executive Director Aaron Smith stated in May 2024 that Schedule III status would "level the playing field for state-licensed businesses that have been operating under an unconstitutional tax burden for decades." The U.S. Cannabis Council, which represents large MSOs, similarly advocated for rescheduling while noting that Schedule III does not resolve all federal-state conflicts, including banking access under the Bank Secrecy Act.

Opposition Groups

Smart Approaches to Marijuana, led by Kevin Sabet, submitted comments opposing rescheduling and arguing that cannabis meets Schedule I criteria. SAM contends that increased potency of modern cannabis products, particularly concentrates and vape cartridges, creates higher abuse potential than the cannabis evaluated in historical studies. The organization has requested party status in the ALJ hearing to present expert testimony. The National Sheriffs' Association and the International Association of Chiefs of Police submitted joint comments expressing concerns about impaired driving and youth access, though neither organization explicitly opposed Schedule III classification.

Legal and Regulatory Framework

The Controlled Substances Act establishes the legal architecture for drug scheduling, with authority divided between the DEA and HHS under 21 U.S.C. § 811.

Scheduling Criteria Under 21 U.S.C. § 812

Schedule I substances must have high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Schedule III substances have currently accepted medical use, potential for abuse less than Schedule I and II substances, and moderate or low potential for physical or psychological dependence. The DEA's May 2024 NPRM concluded that cannabis meets Schedule III criteria based on FDA's finding that cannabis has accepted medical use for anorexia, nausea and vomiting, and pain. The agency cited clinical trials, state medical cannabis programs serving over 800,000 registered patients, and physician recommendations as evidence of accepted medical use.

Administrative Procedure Act Requirements

The rescheduling process must comply with the Administrative Procedure Act, codified at 5 U.S.C. § 551 et seq. The APA requires notice-and-comment rulemaking for substantive rules, including publication in the Federal Register, opportunity for public comment, and consideration of comments in the final rule. The DEA's decision to hold an ALJ hearing exceeds minimum APA requirements and reflects the political sensitivity of cannabis rescheduling.

Internal Revenue Code Section 280E

Section 280E applies to businesses trafficking in Schedule I or Schedule II controlled substances. Once cannabis moves to Schedule III, Section 280E will no longer apply, allowing cannabis businesses to deduct ordinary and necessary business expenses under Section 162. This includes rent, salaries, marketing, professional services, utilities, insurance, and depreciation beyond cost of goods sold. The effective date of tax relief depends on the final rule's effective date. The DEA typically allows 30 to 90 days between publication of a final rule and its effective date. Cannabis businesses will be able to claim deductions for tax years beginning on or after the effective date. Some tax practitioners have argued that businesses could amend prior-year returns if the effective date occurs before the statute of limitations expires, though IRS guidance on this issue remains pending.

Continued Federal Prohibition

Schedule III status does not legalize cannabis under federal law. Cannabis will remain a controlled substance subject to DEA registration requirements, manufacturing quotas, and distribution restrictions. The Controlled Substances Act prohibits possession, distribution, and manufacturing of Schedule III substances without DEA registration. State-licensed cannabis businesses do not hold and cannot obtain DEA registration, creating an ongoing federal-state conflict. However, Schedule III status significantly reduces criminal penalties. Possession of Schedule I substances carries maximum penalties of one year imprisonment for first offense, while Schedule III possession carries maximum penalties of one year only if the amount exceeds certain thresholds. Manufacturing and distribution penalties are also lower for Schedule III substances.

State-by-State Tax and Regulatory Implications

Schedule III reclassification will interact differently with each state's cannabis tax structure, creating varied impacts on retail prices and operator margins.

California

California imposes a 15% excise tax on retail cannabis sales, plus state and local sales taxes averaging 9%. The state eliminated its cultivation tax in July 2022 due to concerns about illicit market competition. Schedule III tax relief will primarily benefit California operators through federal deductions, but will not directly affect state tax obligations. California's cannabis market generated $5.2 billion in sales in 2023, making it the largest state market. Major operators including Glass House Brands and Harborside have projected 25% to 35% margin improvements from Section 280E elimination.

Florida

Florida operates a medical-only cannabis program with no excise tax on cannabis sales, applying only the state's 6% sales tax. The state's vertical integration requirement mandates that license holders control cultivation, processing, and retail. Trulieve holds approximately 50% market share in Florida, with 129 of its 193 dispensaries located in the state. Florida voters will consider adult-use legalization in November 2024 through Amendment 3, which Trulieve has funded with over $60 million in contributions. Schedule III tax relief will disproportionately benefit Florida operators due to the state's lack of additional cannabis-specific taxes.

Illinois

Illinois imposes tiered excise taxes based on THC content: 10% on cannabis flower, 20% on products infused with cannabis such as edibles, and 25% on concentrates. The state generated $1.5 billion in adult-use sales in 2023. Green Thumb Industries, Cresco Labs, and Verano Holdings dominate the Illinois market. Schedule III status will improve operator margins but will not affect state excise tax obligations, which are calculated at the wholesale level.

Michigan

Michigan imposes a 10% excise tax on retail cannabis sales plus 6% sales tax. The state's market generated $3.0 billion in sales in 2023, making it the third-largest state market. Michigan's relatively open licensing structure has created intense price competition, with wholesale flower prices declining to $600 to $800 per pound in 2024 from over $2,000 per pound in 2020. Schedule III tax relief will provide critical margin support for Michigan operators facing commoditized pricing.

New York

New York's adult-use program launched in December 2022 with a complex tax structure including a THC-based tax on distributors and a 13% retail excise tax. The state has issued over 150 retail licenses but faces challenges with illicit market competition and supply chain bottlenecks. Schedule III tax relief will benefit New York operators, though the market remains in early stages with limited profitability.

Ohio

Ohio operates a medical-only program with over 300,000 registered patients. The state does not impose an excise tax on medical cannabis, applying only the 5.75% sales tax. Ohio voters approved adult-use legalization in November 2023, with sales expected to commence in mid-2024. Schedule III status will benefit Ohio operators including Verano, Ayr Wellness, and Buckeye Relief as the market transitions to adult use.

Pennsylvania

Pennsylvania's medical cannabis program serves over 400,000 registered patients with no excise tax on medical sales. The state applies standard sales tax exemptions for medical purchases. Pennsylvania has not legalized adult-use cannabis, though Governor Josh Shapiro has expressed support for legalization. Schedule III tax relief will improve margins for Pennsylvania operators including Trulieve, Jushi Holdings, and TerrAscend.

Market and Business Implications

Schedule III tax relief will trigger the most significant capital reallocation in U.S. cannabis industry history, with implications for mergers and acquisitions, capital expenditures, and competitive positioning.

Margin Expansion and Profitability

Investment analysts project that Schedule III status will improve EBITDA margins for MSOs by 15 to 40 percentage points depending on current tax efficiency and operational leverage. Trulieve, with relatively high gross margins of 50% to 55%, could see EBITDA margins expand from current levels of 25% to 30% to 50% to 60% post-rescheduling. Curaleaf, with lower gross margins of 40% to 45%, could see EBITDA margins expand from 15% to 20% to 35% to 45%. The margin expansion will flow through to net income, with some operators achieving profitability on a GAAP basis for the first time. Green Thumb Industries reported net income of $42 million for fiscal year 2023 despite Section 280E headwinds; analysts project net income could exceed $300 million post-rescheduling.

Mergers and Acquisitions

Schedule III status will unlock M&A activity by improving operator cash flows and reducing the cost of capital. Trulieve's 2021 acquisition of Harvest Health & Recreation for $2.1 billion represented the largest cannabis M&A transaction to date, but deal activity has slowed significantly since 2022 due to capital constraints and valuation compression. Tax relief will enable operators to pursue consolidation strategies, particularly targeting distressed assets in competitive markets like Michigan and Oklahoma. Cross-border M&A between U.S. and Canadian operators may also accelerate. Canopy Growth, Tilray Brands, and Cronos Group have maintained U.S. market entry strategies but have been constrained by Schedule I status. Schedule III could facilitate transactions, though continued federal prohibition may limit Canadian operators' willingness to enter the U.S. market.

Capital Expenditures and Market Expansion

Improved cash flows will allow operators to fund expansion into new markets and upgrade existing facilities. Limited license states including New York, New Jersey, and Connecticut represent high-value expansion opportunities. Schedule III tax relief will also support investments in brand development, product innovation, and retail experience enhancements that have been deferred due to capital constraints.

Wholesale Pricing Dynamics

Tax relief may accelerate wholesale price compression in mature markets as operators pass savings to consumers to gain market share. Wholesale flower prices in California, Michigan, and Oregon have already declined to commodity levels, and Schedule III status could extend this dynamic to newer markets. Operators with low-cost cultivation and vertical integration will benefit disproportionately, while high-cost producers may face continued margin pressure despite tax relief.

Ancillary Business Impacts

Schedule III status will benefit ancillary businesses including real estate investment trusts, equipment suppliers, and software providers. Real estate investors have avoided cannabis properties due to Schedule I stigma and banking complications; Schedule III could attract institutional capital to cannabis real estate. Equipment suppliers including Agrify and GrowGeneration have struggled with customer capital constraints; improved operator cash flows will support equipment purchases and facility upgrades.

What Experts Say

Industry analysts, tax attorneys, and policy experts have offered varied assessments of Schedule III tax relief's magnitude and timeline. Cowen analyst Vivien Azer published research in June 2024 projecting that Schedule III status would add $1.50 to $3.00 per share in value to MSO equities, representing 30% to 60% upside from current trading levels. Azer noted that the market has partially priced in rescheduling expectations, but significant upside remains contingent on final rule implementation. Andrew Kline, a partner at Perkins Coie and former federal prosecutor, stated in a July 2024 webinar that the DEA's decision to hold an ALJ hearing suggests the agency is taking opposition arguments seriously and may modify the final rule in response to public health concerns. Kline projected that the final rule would be published in the first quarter of 2025, with an effective date in mid-2025. Kris Krane, president of 4Front Ventures, said in an August 2024 interview that Schedule III tax relief represents a "game changer" for operators that have maintained disciplined cost structures, but warned that companies with bloated overhead may squander the windfall on executive compensation rather than strategic investments. Rosemary Mazanet, a tax attorney at Vicente Sederberg, explained in a May 2024 client memo that cannabis businesses should begin preparing for Section 280E elimination by documenting all business expenses, reviewing accounting systems, and consulting with tax advisors about amended return strategies for open tax years. Morgan Fox, political director for NORML, stated in a June 2024 press release that Schedule III status represents meaningful progress but falls short of full legalization, leaving state-licensed businesses in a "legal gray zone" that perpetuates banking access challenges and interstate commerce restrictions.

What's Next: Timeline and Decision Points

The DEA's administrative process will determine the timing and scope of Schedule III tax relief, with key milestones expected through the first half of 2025. The administrative law judge hearing is scheduled for November 2024, with testimony expected to span multiple days. The ALJ will issue a recommended decision to the DEA Administrator, typically within 60 to 90 days of the hearing's conclusion. The Administrator may adopt, modify, or reject the ALJ's recommendation. If the DEA proceeds with rescheduling, the agency will publish a final rule in the Federal Register. The final rule will specify an effective date, typically 30 to 90 days after publication. Cannabis businesses will be able to claim deductions under Section 162 for tax years beginning on or after the effective date. Congressional action remains possible but unlikely. Some Republican lawmakers have introduced resolutions of disapproval under the Congressional Review Act, which would allow Congress to overturn the DEA's rule with a simple majority vote. However, President Biden would almost certainly veto such a resolution, and Congress lacks the two-thirds majority needed to override a veto. Litigation challenging the final rule is probable. Smart Approaches to Marijuana and other opposition groups may file suit in federal court arguing that the DEA's rescheduling decision is arbitrary and capricious under the APA. Such litigation could delay implementation but is unlikely to succeed given the deference courts afford agency scientific determinations under Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc. State-level developments will continue in parallel. Florida voters will decide adult-use legalization in November 2024. Pennsylvania, Ohio, and other states are considering legalization legislation. Federal rescheduling may accelerate state-level reforms by reducing political opposition and demonstrating federal acceptance of medical cannabis. The 2024 presidential election could affect implementation timelines. While both major party candidates have expressed support for cannabis reform, a change in administration could alter DEA priorities and enforcement approaches.

Further Reading

• Drug Enforcement Administration, "Schedules of Controlled Substances: Rescheduling of Marijuana," 89 Fed. Reg. 44,597 (May 21, 2024), https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
• Internal Revenue Code Section 280E, 26 U.S.C. § 280E, https://www.law.cornell.edu/uscode/text/26/280E
• Controlled Substances Act, 21 U.S.C. § 801 et seq., https://www.deadiversion.usdoj.gov/21cfr/21usc/index.html
• U.S. Department of Health and Human Services, Letter to DEA Administrator Anne Milgram (August 29, 2023) (on file with DEA)
• National Cannabis Industry Association, Comments on DEA Proposed Rulemaking (July 2024), https://thecannabisindustry.org
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" (updated June 2024), https://crsreports.congress.gov
• Cowen Equity Research, "U.S. Cannabis: Schedule III Deep Dive" (June 18, 2024)
• Trulieve Cannabis Corp., Form 10-K for Fiscal Year Ended December 31, 2023, https://www.sec.gov
• Curaleaf Holdings, Inc., Annual Report for Fiscal Year Ended December 31, 2023, https://www.sedarplus.ca
• Green Thumb Industries Inc., Form 10-K for Fiscal Year Ended December 31, 2023, https://www.sec.gov